IL243264B - גורם מייצב עבור חלבונים רוקחיים - Google Patents

גורם מייצב עבור חלבונים רוקחיים

Info

Publication number
IL243264B
IL243264B IL243264A IL24326415A IL243264B IL 243264 B IL243264 B IL 243264B IL 243264 A IL243264 A IL 243264A IL 24326415 A IL24326415 A IL 24326415A IL 243264 B IL243264 B IL 243264B
Authority
IL
Israel
Prior art keywords
stabilizing agent
pharmaceutical proteins
proteins
pharmaceutical
stabilizing
Prior art date
Application number
IL243264A
Other languages
English (en)
Original Assignee
Octapharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Octapharma Ag filed Critical Octapharma Ag
Publication of IL243264B publication Critical patent/IL243264B/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
IL243264A 2010-04-20 2015-12-21 גורם מייצב עבור חלבונים רוקחיים IL243264B (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32597510P 2010-04-20 2010-04-20
EP10160470 2010-04-20
PCT/EP2011/056326 WO2011131720A1 (en) 2010-04-20 2011-04-20 New stabilizing agent for pharmaceutical proteins

Publications (1)

Publication Number Publication Date
IL243264B true IL243264B (he) 2018-06-28

Family

ID=42697273

Family Applications (3)

Application Number Title Priority Date Filing Date
IL222358A IL222358A0 (en) 2010-04-20 2012-10-11 New stabilizing agent for pharmaceutical proteins
IL243264A IL243264B (he) 2010-04-20 2015-12-21 גורם מייצב עבור חלבונים רוקחיים
IL259921A IL259921B (he) 2010-04-20 2018-06-10 גורם מייצב חדש עבור חלבונים רוקחיים

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL222358A IL222358A0 (en) 2010-04-20 2012-10-11 New stabilizing agent for pharmaceutical proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL259921A IL259921B (he) 2010-04-20 2018-06-10 גורם מייצב חדש עבור חלבונים רוקחיים

Country Status (15)

Country Link
US (4) US20130116410A1 (he)
EP (3) EP2947148B1 (he)
JP (2) JP2013527843A (he)
KR (2) KR102049254B1 (he)
CN (1) CN103003422B (he)
AU (1) AU2011244348B2 (he)
BR (1) BR112012027055B1 (he)
CA (2) CA2796729C (he)
DK (2) DK2561070T3 (he)
ES (2) ES2639641T3 (he)
IL (3) IL222358A0 (he)
MX (1) MX2012012091A (he)
RU (2) RU2707090C2 (he)
WO (1) WO2011131720A1 (he)
ZA (1) ZA201207796B (he)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2707090C2 (ru) 2010-04-20 2019-11-22 Октафарма Аг Новый стабилизатор для фармацевтических белков
US9480966B2 (en) * 2012-04-30 2016-11-01 General Electric Company Substrates and methods for collection, stabilization and elution of biomolecules
US9040679B2 (en) 2012-04-30 2015-05-26 General Electric Company Methods and compositions for extraction and storage of nucleic acids
US9040675B2 (en) 2012-04-30 2015-05-26 General Electric Company Formulations for nucleic acid stabilization on solid substrates
US9044738B2 (en) 2012-04-30 2015-06-02 General Electric Company Methods and compositions for extraction and storage of nucleic acids
RU2015115649A (ru) * 2012-09-27 2016-11-20 Октафарма Аг Тест на гемолитический потенциал фармацевтических продуктов и составов для минимизации риска
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
CN112717125A (zh) * 2012-10-03 2021-04-30 瑞士杰特贝林生物制品有限公司 一种纯化蛋白质的方法
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
US10564150B2 (en) * 2012-12-28 2020-02-18 Cellestis Limited Cell mediated immune response assay
US9534214B2 (en) * 2013-10-31 2017-01-03 General Electric Company Substrates and associated methods for elution of nucleic acids
KR102058864B1 (ko) * 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
CA2944876C (en) * 2014-04-25 2024-09-10 Global Life Sciences Solutions Operations UK Ltd SUBSTRATES AND METHODS FOR THE COLLECTION, STABILIZATION AND ELUTION OF BIOMOLECULES
US20170135386A1 (en) * 2014-06-30 2017-05-18 Tate & Lyle Ingredients Americas Llc Coating compositions for consumable articles
CN107073082B (zh) * 2014-08-20 2021-04-30 博尔托拉制药公司 Xa因子解毒剂的冻干制剂
KR20170071507A (ko) * 2014-10-23 2017-06-23 퀴아젠 사이언시스, 엘엘씨 펩티드 조성물 및 그의 용도
PT3233111T (pt) * 2014-12-19 2024-10-10 Kedrion Biopharma Inc Composição farmacêutica que compreende éniplasminogénio e seus usos
CN108473932B (zh) 2015-09-09 2022-07-15 集联健康有限公司 用于样品收集、稳定化和保存的系统、方法和装置
CA3010565C (en) * 2016-01-12 2024-05-14 Intron Biotechnology, Inc. Freeze-dried formulations of antibacterial protein
CN108883160B (zh) 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
CN110381962B (zh) * 2016-12-21 2023-10-13 孙崇谨 用于血浆蛋白的活性保存的新颖方法
EP3694322B1 (en) 2017-10-09 2024-07-03 Terumo BCT Biotechnologies, LLC Lyophilization container and method of using same
EP3938741B1 (en) 2019-03-14 2024-05-01 Terumo BCT Biotechnologies, LLC Lyophilization container fill fixture, system and method of use
EP4013389A1 (en) * 2019-08-16 2022-06-22 Octapharma AG Stabilizing buffer for factor viii and vwf
CN112798373B (zh) * 2020-12-30 2023-04-25 广州金域医学检验中心有限公司 一种血液本周氏蛋白的检测方法
CN112816595A (zh) * 2021-01-06 2021-05-18 海默斯（重庆）医学生物技术有限公司 一种重组角蛋白液体制剂及其纯度检测方法
WO2022261716A1 (en) * 2021-06-16 2022-12-22 Exopharm Limited Aqueous formulations for preservation of extracellular vesicles
WO2023119277A1 (en) 2021-12-21 2023-06-29 Omrix Biopharmaceuticals Ltd. Highly soluble fibrinogen compositions
CN115201486A (zh) * 2022-06-30 2022-10-18 北京众驰伟业科技发展有限公司 一种检测维生素k依赖性蛋白s活性的试剂盒
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물
CN117723763B (zh) * 2023-12-19 2024-08-16 江苏默乐生物科技股份有限公司 一种冻干液、细胞因子蛋白冻干球及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
WO2000062759A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Dry, mouldable drug formulation
ES2343124T3 (es) 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
AU2002335046A1 (en) * 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
EP2572733A1 (en) * 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
JP4949828B2 (ja) * 2003-03-18 2012-06-13 アレス トレーディング ソシエテ アノニム 溶液中での成長ホルモンの安定化
WO2005014050A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and g-csf
SG151261A1 (en) * 2004-03-11 2009-04-30 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
RU2347574C2 (ru) * 2004-05-27 2009-02-27 Эвиджен, Инк. Способы лечения коагулопатий с использованием сульфатированных полисахаридов
US7851565B2 (en) * 2004-12-21 2010-12-14 Nektar Therapeutics Stabilized polymeric thiol reagents
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
WO2007019331A2 (en) * 2005-08-04 2007-02-15 Nektar Therapeutics Al, Corporation Conjugates of a g-csf moiety and a polymer
US20080090278A1 (en) * 2006-03-31 2008-04-17 Toyo Boseki Kabushiki Kaisha Method for enhancing stability of a composition comprising soluble glucose dehydrogenase (gdh)
CA2671676C (en) * 2006-12-27 2014-04-22 Baxter Healthcare Sa Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
KR20100120289A (ko) * 2008-01-15 2010-11-15 애보트 게엠베하 운트 콤파니 카게 분말상 단백질 조성물 및 이의 제조 방법
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
CN102164943A (zh) 2008-09-24 2011-08-24 稳定技术有限公司 使用糖和聚乙烯亚胺保存多肽的方法
RU2707090C2 (ru) 2010-04-20 2019-11-22 Октафарма Аг Новый стабилизатор для фармацевтических белков

Also Published As

Publication number Publication date
CA2796729A1 (en) 2011-10-27
ES2545893T3 (es) 2015-09-16
CN103003422A (zh) 2013-03-27
IL222358A0 (en) 2012-12-31
KR102049254B1 (ko) 2019-11-28
EP2947148B1 (en) 2017-06-07
RU2012149205A (ru) 2014-05-27
DK2561070T3 (en) 2015-08-17
EP2561070B1 (en) 2015-06-03
KR101872203B1 (ko) 2018-08-02
BR112012027055A2 (pt) 2017-07-11
KR20180075681A (ko) 2018-07-04
EP2561070A1 (en) 2013-02-27
AU2011244348B2 (en) 2015-02-12
JP2017014245A (ja) 2017-01-19
EP2947148A1 (en) 2015-11-25
US20130116410A1 (en) 2013-05-09
KR20130065658A (ko) 2013-06-19
CN103003422B (zh) 2015-02-11
RU2015148882A3 (he) 2019-06-10
US20140221290A1 (en) 2014-08-07
JP2013527843A (ja) 2013-07-04
MX2012012091A (es) 2012-11-29
WO2011131720A1 (en) 2011-10-27
ZA201207796B (en) 2013-07-31
DK2947148T3 (en) 2017-09-18
RU2707090C2 (ru) 2019-11-22
CA3078259A1 (en) 2011-10-27
CA2796729C (en) 2020-06-23
RU2571496C2 (ru) 2015-12-20
ES2639641T3 (es) 2017-10-27
BR112012027055B1 (pt) 2019-09-17
US20190030169A1 (en) 2019-01-31
IL259921A (he) 2018-07-31
US9943600B2 (en) 2018-04-17
RU2015148882A (ru) 2019-01-15
EP3269805A1 (en) 2018-01-17
US20160256555A1 (en) 2016-09-08
US10098956B2 (en) 2018-10-16
AU2011244348A1 (en) 2012-11-01
IL259921B (he) 2020-03-31
BR112012027055A8 (pt) 2018-06-26
JP6457445B2 (ja) 2019-01-23

Similar Documents

Publication Publication Date Title
IL259921B (he) גורם מייצב חדש עבור חלבונים רוקחיים
IL245326B (he) תכשיר רוקחי
IL226245A0 (he) תולדות@של@תרופות
PL2619182T3 (pl) Kompozycja farmaceutyczna
GB201008005D0 (en) Pharmaceutical compounds
IL225457A0 (he) הרכב פרמצבטי
PT2579858E (pt) Composição farmacêutica que contém ivabradina
GB2486567B (en) Pharmaceutical formulation
ZA201301920B (en) Pharmaceutical composition
GB2525835B (en) Pharmaceutical agent
GB201010453D0 (en) Pharmaceutical composition
GB201020161D0 (en) Pharmaceutical compounds
ZA201207375B (en) Stabilized pharmaceutical composition
HUE036784T2 (hu) Alisporivirt tartalmazó gyógyászati készítmények
IL221501A (he) תכשיר רפואי המכיל מירמיסטין
GB201001911D0 (en) Pharmaceutical composition
HUP1000034D0 (en) Novel pharmaceutical agents
GB201108234D0 (en) Pharmaceutical agent
IL223324A (he) תרכובות רוקחיות
GB201020365D0 (en) Pharmaceutical compounds
GB201021361D0 (en) Pharmaceutical Compounds
GB201003950D0 (en) Pharmaceutical compounds
GB201020364D0 (en) Pharmaceutical compounds
GB201005734D0 (en) Pharmaceutical compounds
GB201020068D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed